Ibrolipim
Names
[ CAS No. ]:
133208-93-2
[ Name ]:
Ibrolipim
[Synonym ]:
Ibrolipim
NO 1886
OPF-009
Lipoprotein Lipase Activator
Biological Activity
[Description]:
[Related Catalog]:
[Target]
Lipoprotein lipase (LPL)[1][2][3]
[In Vitro]
[In Vivo]
[References]
Chemical & Physical Properties
[ Density]:
1.44g/cm3
[ Boiling Point ]:
512.5ºC at 760 mmHg
[ Molecular Formula ]:
C19H20BrN2O4P
[ Molecular Weight ]:
451.25100
[ Flash Point ]:
263.7ºC
[ Exact Mass ]:
450.03400
[ PSA ]:
98.23000
[ LogP ]:
5.41218
[ Vapour Pressure ]:
1.29E-10mmHg at 25°C
[ Index of Refraction ]:
1.59
[ Storage condition ]:
2-8°C
MSDS
Safety Information
[ Symbol ]:
GHS06
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301
[ Precautionary Statements ]:
P301 + P310
[ RIDADR ]:
UN 2811 6.1 / PGIII
Articles
Eur. J. Pharmacol. 540(1-3) , 139-46, (2006)
Inflammation, closely associated with obesity, is emerging as an important risk factor for the pathophysiological development of atherosclerosis and diabetes mellitus. Fat balance is critical in the a...
NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1.J. Endocrinol. 1st ed., 204 , 47-56, (2010)
Insulin resistance and dyslipidemia are both considered to be risk factors for metabolic syndrome. Low levels of IGF1 are associated with insulin resistance. Elevation of low-density lipoprotein chole...
Evaluation of induction potency of new drug candidates on CYP1A2 and CYP3A4 using real-time one-step RT-PCR in primary cultures of cryopreserved human hepatocytes.Drug Metab. Pharmacokinet. 24(5) , 446-50, (2009)
This study evaluates the induction potency of new drug candidates on mRNA levels of CYP1A2 and CYP3A4 in primary cultures of cryopreserved human hepatocytes. Analysis was performed by quantitative rea...